News | July 11, 2023
Sumitomo Pharma America launches as new combined organization
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Subscribe To Our Newsletter & Stay Updated
